Search

Your search keyword '"Nielsen FC"' showing total 393 results

Search Constraints

Start Over You searched for: Author "Nielsen FC" Remove constraint Author: "Nielsen FC"
393 results on '"Nielsen FC"'

Search Results

1. Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study

2. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901–2014: a nationwide study

3. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

4. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

5. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

6. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

7. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

8. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

11. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

12. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

13. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

14. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

15. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

16. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

17. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

18. Shared heritability and functional enrichment across six solid cancers

19. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

20. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

21. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

22. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

23. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

24. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

25. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

26. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

27. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

28. C-myc and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors

29. Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

30. Effect of syncytiotrophoblast microvillous membrane treatment on gene expression in human umbilical vein endothelial cells

31. Nuclear transit of human zipcode-binding protein IMP1

36. Na(v)1.8 channelopathy in mutant mice deficient for myelin protein zero is detrimental to motor axons.

38. Genomic alterations in the stepwise progression from normal mucosa to metastasizing oral squamous cell carcinoma.

40. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.

41. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

42. Whole genome sequencing in clinical practice.

43. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

44. Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study.

45. Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.

46. Benchmarking full-length transcript single cell mRNA sequencing protocols.

47. The Incidence, Survival, and HPV Impact of Second Primary Cancer following Primary Oropharyngeal Squamous Cell Carcinoma: A 20-Year Retrospective and Population-Based Study.

48. Extensive genomic analysis in patients with KRAS -mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.

49. Differences in gene expression despite identical histomorphology in sinonasal intestinal-type adenocarcinoma and metastases from colorectal adenocarcinoma.

50. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Catalog

Books, media, physical & digital resources